Atlas Trials

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

Clinical trial NCT01510184 · TERMINATED

Trial details

NCT number
NCT01510184
Sponsor
Spectrum Pharmaceuticals, Inc
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Diffuse Large B-cell LymphomaFollicle Center Lymphoma
Start date
2012-04-19
Primary completion
2014-10-23
Enrollment
79

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.